Would love that, yeah.

Yeah.

And so when we look at prior dendritic cell therapies, you really could put them into two different groups.

There's a couple that, that tried some, uh, you know, really, uh, off the charts approaches, but most approaches were either taking the patient's tumor-derived lysate or mRNA and loading that into the dendritic cell.

And when we think about dendritic cells, they're the master regulator of adaptive immunity.

And so the thought behind dendritic cells was, if we can get dendritic cells to recognize the cancer as a threat, then we'll get the benefits of a complete top-down immune response.

And so we have that same belief, and, and the science would show that.

Um, so as Diakonos moves DOC ten twenty-one into a new Phase 1/2 trial in refractory melanoma and continues its Phase 2 GBM and Phase 1 pancreatic cancer programs like we were talking about, uh, what would you say are the most important scientific and operational milestones you and your team have focused on? Uh, and then how do you see these programs informing the next generation of dendritic cell-based immunotherapies?